2023-10-07 05:07:58
Title: New Dementia Drug Shows Promise in Slowing Memory Loss
Publication: HomePanorama
Date: October 7th, 2023
Author: Michelle Mantey
A new drug for dementia, called Leqembi, is offering hope to patients in the early stages of the disease. Developed by Japanese pharmaceutical company Eisai and Biogen from the USA, Leqembi contains the active ingredient lecanemab, which is administered through an infusion. The drug has been tested in scientific studies in the USA and was approved by the American Food and Drug Administration (FDA) on July 6, 2023.
Unlike other dementia drugs that aim to stimulate brain performance, Leqembi targets the protein deposits that occur in the brains of those affected by the disease. These deposits obstruct the transmission of information in the brain, leading to the death of nerve cells. By targeting these proteins, lecanemab aims to slow down the progression of the disease in early-stage patients. It is worth noting that the first signs of dementia can be noticeable several years before a formal diagnosis.
A phase 3 study involving 1,795 participants found that the use of Leqembi slowed the progression of the disease by 27 percent. According to a report from the Daily News, the drug delayed memory loss by approximately five months, a significant achievement considering no such development was observed in the control group that received a placebo.
FDA Neurology Drugs Director Teresa Buracchio commented on the study, stating, “This confirmatory study demonstrated that it is a safe and effective treatment for patients with Alzheimer’s disease.” However, it was noted that 17 percent of the test subjects experienced brain swelling, and three deaths occurred during the study. It is important to highlight that these deaths were not attributed to the drug. Despite these challenges, the costly medication has gained approval in the United States. The manufacturer has already submitted an application for approval to the European Medicines Agency (EMA), indicating a potential expansion of availability in the near future.
It is essential to mention that Alzheimer’s and dementia can affect individuals under the age of 65 as well. The German Alzheimer Society believes that there may be more people affected by these conditions than currently known.
While the new drug offers promising effects in slowing down memory loss and addressing the root cause of the disease, it is crucial to consult a healthcare professional for an accurate diagnosis and to explore appropriate treatment options. Additionally, the use of medication or nutritional supplements should be discussed with a doctor before initiation.
As research and development in the field of dementia continue, scientists and pharmaceutical companies hope to bring new breakthroughs to the market, providing relief and improved quality of life for those affected by this widespread illness.]
#Breakthrough #research #dementia #drug #great #hope